Advances in pharmacotherapy for heart failure and reduced ejection fraction: what's new in 2024?
Ismail, Zahra Aboughdir, Maryam Duric, Bea Kakar, Sahil Chan, Jeffrey Shi Kai Bayatpoor, Yasmin Harky, Amer
Ismail, Zahra
Aboughdir, Maryam
Duric, Bea
Kakar, Sahil
Chan, Jeffrey Shi Kai
Bayatpoor, Yasmin
Harky, Amer
Citations
Altmetric:
Affiliation
Other Contributors
Publication date
2024-10-03
Subject
Collections
Research Projects
Organizational Units
Journal Issue
Abstract
Introduction: Updated guidelines for heart failure with reduced ejection fraction (HFrEF) and acute decompensation have improved outcomes, but ongoing efforts are focused on uncovering new evidence and developing novel therapies. This review examines the limitations of current treatments and the potential impact of emerging therapies.
Areas covered: A literature search focused on studies investigating drugs for HFrEF. We review recent clinical trials and emerging therapies to assess evidence strength, explore guideline updates, and identify strategies to optimize patient outcomes.
Expert opinion: The HFrEF treatment landscape is rapidly evolving, with advances in therapies like sodium/glucose cotransporter inhibitors and sacubitril-valsartan. Though managing acute decompensated heart failure remains challenging, recent trials suggest improvements in diuretic strategies and anti-inflammatory treatments. Ongoing research is essential for validating these therapies and incorporating them into standard practice.
Citation
Ismail Z, Aboughdir M, Duric B, Kakar S, Chan JSK, Bayatpoor Y, Harky A. Advances in pharmacotherapy for heart failure and reduced ejection fraction: what's new in 2024? Expert Opin Pharmacother. 2024 Oct;25(14):1887-1902. doi: 10.1080/14656566.2024.2408376. Epub 2024 Oct 3.
Type
Article
Other
Other